​For U.S. Healthcare Professionals Only

ANAVIP [Crotalidae Immune F(ab’)2 (Equine)] is an equine-derived antivenin indicated for the management of adult and pediatric patients with North American rattlesnake envenomation. IMPORTANT SA

​Introducing ANAVIP®​​​​​​
Pharmacokinetics Matter1

Now Available for Purchase

To order ANAVIP, please call: 1-866-830-7350 or contact your wholesaler.
To report suspected reactions, call: 1-877-851-1902.

Your Heading Here

ANAVIP Dosing Information

Rapid reconstitution and room temperature storage allow ANAVIP to be stocked at the point of care*

  • ​Reconstitute in less than 1 minute per vial
  • ​Store at room temperature up to 25°C (77°F)
  • ​Brief temperature excursions are permitted up to 40°C (104°F)
  • ​DO NOT FREEZE

Achieve initial control by halting the symptoms of envenomation*

  • ​Local signs of envenomation are not progressing
  • ​Systemic symptoms are resolved
  • ​Coagulation parameters have normalized or are trending toward normal

Dose quickly with no maintenance dosing required*

Anavip Dosing Chart

​​* See Package Insert for full prescribing information.

​

1 Bush S, Ruha A, Seifert S, et al. Comparison of F(ab')2 versus Fab antivenom for pit viper envenomation: A prospective, blinded, multicenter, randomized clinical trial. Clin Tox. 2015;53(1):37-45.​

 

INDICATION
ANAVIP [Crotalidae Immune F(ab’)2 (Equine)] is an equine-derived antivenin indicated for the management of adult and pediatric patients with North American rattlesnake envenomation.

ADVERSE REACTIONS
The most common adverse reactions observed in more than 2 percent of patients in the clinical trials for Anavip were: pruritus, nausea, rash, arthralgia, peripheral edema, erythema, headache, myalgias, pain in extremity, and vomiting.

WARNINGS AND PRECAUTIONS
Hypersensitivity
Anavip may cause allergic reactions.

  • Patients with known allergies to horse protein are particularly at risk for an anaphylactic reaction. If signs or symptoms of anaphylaxis or hypersensitivity reactions (including urticaria, rash, tightness of the chest, wheezing, hypotension) occur, discontinue immediately and institute appropriate treatment.
  • Monitor patients with follow-up visits for signs and symptoms of delayed allergic reactions or serum sickness (rash, fever, myalgia, arthralgia, pruritus, urticarial rash) and treat appropriately if necessary.

Transmissible Infectious Agents
Anavip is made from equine (horse) plasma and may therefore carry a risk of transmitting infectious agents, e.g., viruses.

Reactions to Cresol
Trace amounts of cresol from the manufacturing process are contained in Anavip. Localized reactions and generalized myalgias have been reported with the use of cresol as an injectable excipient.

* See Package Insert for full prescribing information.

Rare Disease Therapeutics, Inc.
Laboratorios Silanes
Instituto Bioclon
© 2018 Rare Disease Therapeutics, Inc. All Rights Reserved. Intended for U.S. Audience Only.
CONTACT US | PRIVACY STATEMENT & TERMS OF USE | RDT ANAVIP WEB 003